Industry Trends Show RNA Targeting Small Molecule Drug Discovery Market Set to Expand at 22.9% CAGR Until 2029
Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.
Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.
What Is the Current and Projected Market Size of the RNA Targeting Small Molecule Drug Discovery Industry?
In recent times, the market size for RNA targeting small molecule drug discovery has seen exponential expansion. The expected expansion goes from $1.76 billion in 2024 to $2.13 billion in 2025, with a compound annual growth rate (CAGR) of 20.8%. Factors contributing to this growth during the historic period include a heightened understanding of genetic diseases, revelations in genomics and proteomics, challenges with drug resistance, investment in research for biotechnology and pharmaceuticals, as well as the emergence of RNA therapeutics.
In the coming years, substantial growth is anticipated in the RNA targeting small molecule drug discovery market, with predictions estimating it will reach “$4.85 billion by 2029, boasting a compound annual growth rate (CAGR) of 22.9%. Several factors underlie this projected growth during the forecasted period, including the increasing focus on RNA epigenetics research, RNA-seq and functional genomics, the use of artificial intelligence (AI), patient-focused strategies, and exosome-assisted drug delivery. Further growth is expected from forthcoming developments in the sector including the advent of RNA editing technologies, advancements in the sphere of CRISPR technology, innovative tech advancements, cutting-edge RNA biology, and the application of RNA targeting in the treatment of neurodegenerative diseases.
Download The Free Sample Report Here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=12480&type=smp
#Which Factors Are Currently Driving The Growth Of The RNA Targeting Small Molecule Drug Discovery Market?
The escalating occurrences of cancer, genetic maladies, and viral infections are projected to accelerate the expansion of the RNA-targeted small-molecule drug discovery market. Cancer refers to a set of illnesses marked by uncontrolled cell proliferation in the body, while viral infections are illnesses incited by viruses, minuscule infectious organisms that can only multiply within the cells of living creatures. Drug discovery based on RNA targeting is employed in treating cancer, genetic conditions, and viral infections, as these diseases are inherently tied with genetic aspects and defective genetic matter, which are addressable using medications engineered through RNA targeting techniques. For example, the World Health Organization, an intergovernmental entity based in Switzerland, reported in February 2024, that there were around 20 million new cancer cases and 9.7 million fatalities across the world in 2022. Among these, lung cancer was the most prevalent with 2.5 million new cases (12.4%), succeeded by breast cancer in women (2.3 million cases, 11.6%), colorectal cancer (1.9 million cases, 9.6%), prostate cancer (1.5 million cases, 7.3%), and stomach cancer (970,000 cases, 4.9%). The number of new cancer cases is anticipated to surge by 77% by 2050, escalating to over 35 million annually. Therefore, the burgeoning prevalence of cancer, genetic abnormalities, and viral infections paves the way for the growth of the RNA-targeted small-molecule drug discovery market.
The rna targeting small molecule drug discovery market covered in this report is segmented –
1) By Target RNA Type: Messenger RNA (mRNA), Non-Coding RNA (ncRNA), MicroRNA (miRNA), Long Non-Coding RNA (lncRNA)
2) By Technology: CRISPR-Cas9, RNA Aptamers, Small Interfering RNA (siRNA), Ribozymes, Other Technologies
3) By Therapeutic Area: Oncology, Neurology, Infectious Disease, Metabolic Diseases, Genetic Disorders, Other Therapeutic Areas
4) By Delivery Method: Intravenous (IV), Oral, Topical, Other Methods
5) By Application: Research Use, Therapeutic Use, Diagnostic Use, Other Applications
Subsegments:
1) By Messenger RNA (mRNA): Targeting mRNA For Protein Coding, Modulation Of mRNA Stability, mRNA Translation Inhibition
2) By Non-Coding RNA (ncRNA): Long Non-Coding RNA, Small Nuclear RNA, Small Nucleolar RNA
3) By MicroRNA (miRNA): miRNA Inhibition, miRNA Mimics, Targeting Specific miRNA Pathways
4) By Long Non-Coding RNA (lncRNA): lncRNA Modulators, Targeting Specific lncRNA Functions, Therapeutic Applications Of lncRNA
What Upcoming Trends Are Expected To Impact The RNA Targeting Small Molecule Drug Discovery Market Globally?
The increasing use of artificial intelligence (AI) in drug discovery is a notable trend in the small-molecule drug discovery market. In order to maintain market position, major companies in this market are exploiting AI technology to speed up drug discovery processes. For instance, Google Cloud, a computing service of the US tech company Google, launched the Target and Lead Identification Suite and Multiomics Suite in May 2023. These offerings are designed to streamline the drug discovery process. The Multiomics Suite hastens the identification and analysis of genetic information, helping companies develop precision medicines. Meanwhile, the Target and Lead Identification Suite helps researchers gain better insights into the role of amino acids and to predict protein structures.
Who Are The Main Participants Shaping The RNA Targeting Small Molecule Drug Discovery Market Landscape?
Major companies operating in the RNA targeting small molecule drug discovery market include F. Hoffmann-La Roche Ltd, Merck & Co. Inc, Bayer AG, Novartis AG, Sanofi SA, Bristol-Myers Squibb Company, AstraZeneca PLC, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Amgen Inc., Moderna Inc., Astellas Pharma Inc., Biogen Inc., Alnylam Pharmaceuticals Inc., Sarepta Therapeutics Inc., Evotec A.G., PTC Therapeutics Inc., Ionis Pharmaceuticals Inc., Dicerna Pharmaceuticals Inc., Arrakis Therapeutics, Arbutus Biopharma Corporation, H3 Biomedicine Inc., Anima Biotech Inc., Ribometrix Inc., Quark Pharmaceuticals Inc., Regulus Therapeutics Inc., Skyhawk Therapeutics Inc., Accent Therapeutics Inc., Epics Therapeutics, Expansion Therapeutics
Which Region Currently Holds The Largest Share In The RNA Targeting Small Molecule Drug Discovery Market?
North America was the largest region in the RNA-targeting small molecule drug discovery market in 2024. The regions covered in the RNA targeting small molecule drug discovery market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
Request For A Customized Report:
https://www.thebusinessresearchcompany.com/customise?id=12480&type=smp
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
